| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0885066609335660 |
| P698 | PubMed publication ID | 19617229 |
| P2093 | author name string | Robert P Baughman | |
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I | Q24314556 | ||
| Plasmid-determined AmpC-type beta-lactamases | Q24535748 | ||
| Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia | Q28286874 | ||
| Multidrug-resistant Acinetobacter baumannii | Q28306885 | ||
| Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. | Q54058575 | ||
| Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. | Q54146487 | ||
| Survey of the susceptibility of urinary isolates to antibacterial agents in 2003. | Q54490883 | ||
| Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. | Q54689513 | ||
| The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia | Q57238120 | ||
| Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics | Q48611808 | ||
| Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial | Q51643088 | ||
| Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). | Q51804187 | ||
| Of Pseudomonas, porins, pumps and carbapenems | Q54018502 | ||
| Influence of the MexA-MexB-oprM multidrug efflux system on expression of the MexC-MexD-oprJ and MexE-MexF-oprN multidrug efflux systems in Pseudomonas aeruginosa | Q54027874 | ||
| Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae | Q54042026 | ||
| Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns | Q54049533 | ||
| Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem | Q28378163 | ||
| Emergence of resistance to imipenem in Pseudomonas aeruginosa | Q30451746 | ||
| National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. | Q30977541 | ||
| Antimicrobial resistance in intensive care units | Q33673770 | ||
| In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis | Q33836698 | ||
| Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription | Q33912931 | ||
| Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia | Q33921191 | ||
| Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem | Q33935441 | ||
| Practice guidelines for the management of bacterial meningitis | Q33982444 | ||
| Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. | Q33982975 | ||
| Cefepime, Piperacillin-Tazobactam, and the Inoculum Effect in Tests with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae | Q33983667 | ||
| Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients | Q34052619 | ||
| SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae | Q34073514 | ||
| Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units) | Q34111057 | ||
| 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer | Q34114674 | ||
| Controversies about extended-spectrum and AmpC beta-lactamases | Q34213755 | ||
| Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock | Q34314380 | ||
| Overview of nosocomial infections caused by gram-negative bacilli | Q34444001 | ||
| Practice guidelines for the diagnosis and management of skin and soft-tissue infections | Q34460523 | ||
| Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials | Q34475273 | ||
| The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting | Q34509624 | ||
| Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. | Q34510547 | ||
| Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial | Q34569412 | ||
| Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England | Q34571574 | ||
| Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species | Q35014507 | ||
| AmpC beta-lactamases: what do we need to know for the future? | Q35140531 | ||
| Nosocomial infections adversely affect the outcomes of patients with serious intraabdominal infections | Q35772778 | ||
| Is it safe to use carbapenems in patients with a history of allergy to penicillin? | Q35919005 | ||
| Clinical outcome of bacteremic spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. | Q35936876 | ||
| Appropriate and timely empirical antimicrobial treatment of icu infections--a role for carbapenems | Q36219506 | ||
| Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options | Q36268383 | ||
| Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems | Q36275481 | ||
| Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. | Q36282000 | ||
| An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. | Q36344982 | ||
| Doripenem | Q36538130 | ||
| Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential | Q36670323 | ||
| Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia | Q36856249 | ||
| Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases | Q37120635 | ||
| Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy | Q37624439 | ||
| Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella | Q39477943 | ||
| Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients | Q39487652 | ||
| Experience with a clinical guideline for the treatment of ventilator-associated pneumonia | Q39570112 | ||
| Postantibiotic effect of imipenem on Pseudomonas aeruginosa | Q39849241 | ||
| Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model. | Q40438901 | ||
| Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. | Q40558538 | ||
| Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial | Q40612851 | ||
| Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy | Q40704822 | ||
| Beta-lactam regimens for the febrile neutropenic patient | Q40765968 | ||
| Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients | Q40788084 | ||
| Determinants of the activity of beta-lactamase inhibitor combinations | Q40884640 | ||
| Acquired carbapenemases | Q41530522 | ||
| High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. | Q42054872 | ||
| Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae | Q42167308 | ||
| Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia | Q42537148 | ||
| In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients | Q43203176 | ||
| Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region | Q43587147 | ||
| Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. | Q43587157 | ||
| In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains | Q43758464 | ||
| Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? | Q43874264 | ||
| Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia | Q44088492 | ||
| Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). | Q44266804 | ||
| Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center | Q44685672 | ||
| Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). | Q44719256 | ||
| Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis | Q44808648 | ||
| Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy | Q44850126 | ||
| Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis | Q44930989 | ||
| Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome | Q45097000 | ||
| The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe | Q45170003 | ||
| Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. | Q45216688 | ||
| Ertapenem-associated seizures in a peritoneal dialysis patient | Q45219997 | ||
| Acute seizures due to a probable interaction between valproic acid and meropenem. | Q45258188 | ||
| In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase | Q46435439 | ||
| Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms | Q46476490 | ||
| Seizure worsening caused by decreased serum valproate during meropenem therapy | Q46558607 | ||
| Epidemiology and microbiology of hospital-acquired pneumonia | Q46641627 | ||
| Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program | Q46733453 | ||
| Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program | Q46744338 | ||
| Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan | Q46782435 | ||
| Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). | Q46819792 | ||
| Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. | Q46855855 | ||
| Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program | Q46909106 | ||
| Respiratory nosocomial infections in the medical intensive care unit | Q47843096 | ||
| Important and Emerging β-Lactamase-mediated Resistances in Hospital-based Pathogens: The Amp C Enzymes | Q47946026 | ||
| Aminoglycosides for intra-abdominal infection: equal to the challenge? | Q47972158 | ||
| P433 | issue | 4 | |
| P921 | main subject | carbapenem antibiotic | Q410897 |
| P304 | page(s) | 230-241 | |
| P577 | publication date | 2009-07-17 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal of Intensive Care Medicine | Q6295377 |
| P1476 | title | The use of carbapenems in the treatment of serious infections | |
| P478 | volume | 24 |
| Q40158594 | A permission system for carbapenem use reduced incidence of drug-resistant bacteria and cost of antimicrobials at a general hospital in Japan |
| Q36417501 | Acinetobacter baumanniiSepticemia in a Recipient of an Allogeneic Hematopoietic Stem Cell Transplantation |
| Q27660367 | Biochemical and Structural Characterization of Mycobacterium tuberculosis β-Lactamase with the Carbapenems Ertapenem and Doripenem |
| Q53714289 | Carbapenem Resistance: A Review |
| Q38052888 | Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis |
| Q92327785 | Comparison of Four Commercial Screening Assays for the Detection of blaKPC, blaNDM, blaIMP, blaVIM, and blaOXA48 in Rectal Secretion Collected by Swabs |
| Q38865064 | Comparison of in vitro activities of meropenem productions on Klebsiella pneumoniae isolated from hospitalized patients |
| Q37825731 | Current challenges in the management of the infected patient |
| Q92289384 | Detection of Enterobacterales resistant to polymyxins using Rapid Polymyxins NP test |
| Q36396195 | Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach |
| Q50876503 | Epidemiology and antimicrobial resistance among commonly encountered bacteria associated with infections and colonization in intensive care units in a university-affiliated hospital in Shanghai |
| Q38016195 | Extended spectrum β-lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria. |
| Q34800304 | Identification of Products of Inhibition of GES-2 β-Lactamase by Tazobactam by X-ray Crystallography and Spectrometry |
| Q92353271 | In vitro activities of colistin, imipenem and ceftazidime against drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates in the south of Iran |
| Q37810405 | Management of Complicated Urinary Tract Infections in the Era of Antimicrobial Resistance |
| Q59101206 | Mutant prevention concentrations of imipenem and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii |
| Q88801950 | Pharmacokinetics of imipenem in plasma and cerebrospinal fluid in patients with intracerebral hemorrhage |
| Q36029984 | Prevalence and Fate of Carbapenemase Genes in a Wastewater Treatment Plant in Northern China. |
| Q27670446 | Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 2. N-Alkylated and open chain analogs of MK-8712 |
| Q33992526 | Urinary Tract Infections in the Elderly Population |
| Q38872374 | β-Lactams and β-Lactamase Inhibitors: An Overview |
Search more.